CLL highlights from ASCO 2016: HELIOS trial, CAR T-cell therapy and CLL-IPI
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma
Jesús San Miguel
What are the genetic and environmental risk factors for chronic lymphoblastic leukemia (CLL)?
Why daratumumab will become key for the treatment of multiple myeloma